We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Roche, Netflix, NIKE, Uber, Technologies and Prologis
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 12, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Netflix, Inc. (NFLX - Free Report) , NIKE, Inc. (NKE - Free Report) , Uber Technologies, Inc. (UBER - Free Report) and Prologis, Inc. (PLD - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Roche, Netflix and NIKE
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG, Netflix, Inc. and NIKE, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Roche have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-2.1% vs. +18.7%). The company's performance in 2023 has been impacted by lower COVID-19-product-related sales, which has significantly impacted its top line, even though the diagnostics base business and newer drugs maintain growth.
Sales are likely to be affected further by the expected nosedive in sales of COVID-19 products worth nearly CHF 4.5 billion. Competition from biosimilars for established cancer medicines like Avastin, MabThera/Rituxan and Herceptin also hurt sales.
Nevertheless, new drugs -- namely Ocrevus, Hemlibra, Evrysdi, Phesgo, Polivy and Tecentriq -- have put up a stellar performance. The uptake of its new eye drug, Vabysmo, has been outstanding. The company's efforts to develop new drugs to combat the decline in legacy drugs are encouraging.
Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the past year (+44.9% vs. +19.6%). The company is benefiting from a growing subscriber base thanks to a robust portfolio. Crackdown on password-sharing and the introduction of paid sharing in more than 100 countries, which represents more than 80% of Netflix's revenue base, is also expected to aid growth.
Netflix's diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content, has been driving its growth prospects.
However, stiff competition in the streaming space from the likes of Apple, Amazon Prime Video, Disney+, Peacock and Paramount+ is a headwind. Netflix's leveraged balance sheet and a higher streaming obligation are concerns. Additionally, unfavorable forex is expected to hurt operating income in the fourth quarter of 2023.
Shares of NIKE have declined -3.1% over the past six months against the Zacks Shoes and Retail Apparel industry's decline of -5.7%. The company's continued progress on Consumer Direct Acceleration strategy, compelling product innovation and digital leadership have been drivers.
This aided retail sales across Nike Direct and wholesale businesses in first-quarter fiscal 2024. The digital business has been gaining from robust consumer trends, including momentum in the NIKE mobile app led by improved traffic and increased member buying frequency. The company posted top and bottom-line growth in first-quarter fiscal 2024.
Backed by solid consumer momentum, a robust innovation pipeline and strong inventory, management provided solid outlook for fiscal 2024. However, NIKE has been witnessing gross margin pressures owing to the rising inflation. Elevated demand creation expenses lead to higher SG&A expense.
Other noteworthy reports we are featuring today include Uber Technologies, Inc. and Prologis, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Roche, Netflix, NIKE, Uber, Technologies and Prologis
For Immediate Release
Chicago, IL – January 12, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Netflix, Inc. (NFLX - Free Report) , NIKE, Inc. (NKE - Free Report) , Uber Technologies, Inc. (UBER - Free Report) and Prologis, Inc. (PLD - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Roche, Netflix and NIKE
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG, Netflix, Inc. and NIKE, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Roche have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-2.1% vs. +18.7%). The company's performance in 2023 has been impacted by lower COVID-19-product-related sales, which has significantly impacted its top line, even though the diagnostics base business and newer drugs maintain growth.
Sales are likely to be affected further by the expected nosedive in sales of COVID-19 products worth nearly CHF 4.5 billion. Competition from biosimilars for established cancer medicines like Avastin, MabThera/Rituxan and Herceptin also hurt sales.
Nevertheless, new drugs -- namely Ocrevus, Hemlibra, Evrysdi, Phesgo, Polivy and Tecentriq -- have put up a stellar performance. The uptake of its new eye drug, Vabysmo, has been outstanding. The company's efforts to develop new drugs to combat the decline in legacy drugs are encouraging.
(You can read the full research report on Roche here >>>)
Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the past year (+44.9% vs. +19.6%). The company is benefiting from a growing subscriber base thanks to a robust portfolio. Crackdown on password-sharing and the introduction of paid sharing in more than 100 countries, which represents more than 80% of Netflix's revenue base, is also expected to aid growth.
Netflix's diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content, has been driving its growth prospects.
However, stiff competition in the streaming space from the likes of Apple, Amazon Prime Video, Disney+, Peacock and Paramount+ is a headwind. Netflix's leveraged balance sheet and a higher streaming obligation are concerns. Additionally, unfavorable forex is expected to hurt operating income in the fourth quarter of 2023.
(You can read the full research report on Netflix here >>>)
Shares of NIKE have declined -3.1% over the past six months against the Zacks Shoes and Retail Apparel industry's decline of -5.7%. The company's continued progress on Consumer Direct Acceleration strategy, compelling product innovation and digital leadership have been drivers.
This aided retail sales across Nike Direct and wholesale businesses in first-quarter fiscal 2024. The digital business has been gaining from robust consumer trends, including momentum in the NIKE mobile app led by improved traffic and increased member buying frequency. The company posted top and bottom-line growth in first-quarter fiscal 2024.
Backed by solid consumer momentum, a robust innovation pipeline and strong inventory, management provided solid outlook for fiscal 2024. However, NIKE has been witnessing gross margin pressures owing to the rising inflation. Elevated demand creation expenses lead to higher SG&A expense.
(You can read the full research report on NIKE here >>>)
Other noteworthy reports we are featuring today include Uber Technologies, Inc. and Prologis, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.